IDiyas

For the Inventor, By the Inventor

Melrose, MA, United States of America

Andrew J McRiner

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • Centerport, NY (US) (2011 - 2014)
  • Winchester, MA (US) (2017 - 2018)
  • Melrose, MA (US) (2012 - 2019)

Company Filing History:

goldMedal7 out of 41 
 
Dart Neuroscience, (cayman) Ltd.
 patents
silverMedal3 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
bronzeMedal3 out of 8 
 
Axovant Sciences Gmbh
 patents
4. 2 out of 44 
 
Ironwood Pharmaceuticals, Inc.
 patents
5. 2 out of 51 
 
Denali Therapeutics Inc.
 patents
6. 1 out of 10 
 
Helicon Therapeutics, Inc.
 patents

Years Active: 2011-2019

Loading Chart...
Loading Chart...
18 patents (USPTO):
1. 10428062 - Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors (2019-10-01),
2. 10370370 - Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors (2019-08-06),
3. 10183938 - Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors (2019-01-22),
4. 10053467 - Therapeutic isoxazole compounds (2018-08-21),
5. 9969742 - Imidazotriazinone compounds (2018-05-15),
6. 9802927 - Oxadiazine compounds and methods of use thereof (2017-10-31),
7. 9771378 - Fused morpholinopyrimidines and methods of use thereof (2017-09-26),
8. 9725453 - Imidazotriazinone compounds (2017-08-08),
9. 9650349 - Therapeutic isoxazole compounds (2017-05-16),
10. 9227971 - Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors (2016-01-05),
11. 9029397 - Therapeutic isoxazole compounds (2015-05-12),
12. 8921399 - Therapeutic isoxazole compounds (2014-12-30),
13. 8791137 - Therapeutic compounds (2014-07-29),
14. 8703784 - Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin (2014-04-22),
15. 8591943 - Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors (2013-11-26),

Title: **Andrew J McRiner: Innovator in Cognitive Function Enhancement**

Introduction

Andrew J McRiner, based in Melrose, MA, is a notable inventor with a focus on pharmaceutical innovations aimed at enhancing cognitive function. With a commendable 18 patents to his name, McRiner has made significant contributions to the field of neuroscience.

Latest Patents

McRiner’s latest inventions include the development of novel geminal substituted aminobenzisoxazole compounds that act as agonists of α7-nicotinic acetylcholine receptors. These compounds and their pharmaceutical compositions are designed for use in maintaining, treating, and improving cognitive function. Additionally, he has developed aminobenzisoxazole compounds that serve similar therapeutic purposes, illustrating a consistent focus on cognitive enhancement and methods for administering these innovative compounds to patients with cognitive deficiencies.

Career Highlights

Throughout his career, McRiner has collaborated with prominent organizations such as Dart Neuroscience and Merck Sharp & Dohme Corporation. His experiences at these esteemed companies have undoubtedly shaped his understanding and approach to pharmaceutical innovation.

Collaborations

In his journey, McRiner has worked alongside skilled professionals such as Alan P Kaplan and Terence P Keenan. These collaborations have enriched his work, allowing for a blend of ideas and expertise that contributes to his innovative advancements.

Conclusion

Andrew J McRiner continues to be a key player in the realm of cognitive health innovation. His dedication to developing compounds that bolster cognitive function showcases the critical role of inventors in advancing medical science and improving quality of life through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…